We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Blocking MicroRNA Synthesis Reverses Behavior of Tumor-Associated Macrophages

By LabMedica International staff writers
Posted on 22 Jun 2016
Preventing synthesis of microRNAs in compromised tumor associated macrophages (TAMs) reprograms these cells from being tumor supporting to being tumor suppressing.

TAMs largely express an alternatively activated (or M2) phenotype, which entails immunosuppressive and tumor-promoting capabilities. More...
Reprogramming TAMs towards a classically activated (M1) phenotype might reverse tumor-associated immunosuppression and activate anti-tumor immunity.

To test this possibility, investigators at Ecole Polytechnique Fédérale de Lausanne (Switzerland) used genetic engineering techniques to conditionally delete the microRNA (miRNA)-processing enzyme DICER1 in macrophages. The enzyme Dicer, which is encoded by the DICER1 gene, trims double stranded RNA, to form small interfering RNA (siRNA) or microRNA (miRNA). These processed RNAs are incorporated into the RNA-induced silencing complex (RISC), which targets messenger RNA to prevent translation.

The investigators reported in the June 13, 2016, online edition of the journal Nature Cell Biology that deletion of DICER1 prompted M1-like TAM programming, characterized by hyperactive IFN (interferon)-gamma/STAT1 (signal transducer and activator of transcription 1) signaling. This behavior modification eliminated the immunosuppressive capacity of TAMs and fostered the recruitment of activated cytotoxic T lymphocytes (CTLs) to the tumors. CTL-derived IFN-gamma increased the M1 polarization of DICER1-deficient TAMs and inhibited tumor growth.

Genetic rescue of Let-7 miRNA activity in DICER1-deficient TAMs partly restored their M2-like phenotype and decreased tumor-infiltrating CTLs. These findings suggested that DICER1/Let-7 microRNA activity opposed IFN-gamma-induced, immunostimulatory M1-like TAM activation.

"The most exciting finding was that TAM reprogramming greatly improved the efficacy of immunotherapy," said senior author Dr. Michele De Palma, a tenure track assistant professor at the Ecole Polytechnique Fédérale de Lausanne. "Our results in experimental models of cancer suggest a new therapeutic strategy based on inhibiting the microRNA machinery - or the Let-7 microRNAs - specifically in the TAMs, which may unleash the power of mainstream immunotherapies, such as immune checkpoint inhibitors."

Related Links:
Ecole Polytechnique Fédérale de Lausanne


New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
Serological Pipet Controller
PIPETBOY GENIUS
New
Candida Glabrata Test
ELIchrom Glabrata
New
Silver Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.